Feinberg School of Medicine, presented the data, marking the first public presentation of this data. The primary objectives of the study were to evaluate the safety and tolerability of escalating doses of JVS-100, a non-viral gene therapy expressing stromal cell-derived factor 1 , delivered via direct intramuscular injection to patients with CLI.
http://ift.tt/1xAshQk
http://ift.tt/1xAshQk
No comments:
Post a Comment